Neuromyelitis Optica

Safer biologics to treat Neuromyelitis Optica

neuromyelitis optica

(NMO)

Neuromyelitis Optica (NMO) is a rare disease and no treatment is currently approved by the FDA. Role of complement alternative pathway is certain in the disease as eculizumab has shown benefit in this disease in phase II trial. Alternative complement pathway not only results in tissue injury and cell death but also produces two potent anaphylatoxins C3a and C5a responsible for producing inflammatory molecules such as TNF-alpha, IL-1ß, IL-6, IL-7, IL-8, IL-17, IL-18 and VEGF. Inhibition of C3a formation is critical for controlling inflammation. Whereas eculizumab only inhibits C5a/C5b, our lead drug candidate inhibits C3a/C3b and C5a/C5b which are certainly important in NMO.  
A therapeutic agent that selectively inhibits the alternative pathway and prevents formation of C3b/C3a, C5b/C5a, and MAC is expected to provide therapeutic benefit in NMO.
A therapeutic agent that selectively inhibits alternative pathway and prevents formation of C3b/C3a, C5b/C5a, and MAC is expected to provide therapeutic benefit in NMO.

Collaborate with novelmed